• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

    9/19/24 8:16:37 AM ET
    $SILK
    Medical/Dental Instruments
    Health Care
    Get the next $SILK alert in real time by email
    SC 13D/A 1 tm2424348d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    SILK ROAD MEDICAL, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $.001

     

    (Title of Class of Securities)

     

    82710M100

     

    (CUSIP Number of Class of Securities)

     

    David J. Snyderman

    Magnetar Capital LLC

    1603 Orrington Ave.

    Evanston, Illinois 60201

    (847) 905-4400

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    September 17, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 82710M100  SCHEDULE 13D Page 2 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Financial LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)       ¨

    (b)       x

    3. SEC USE ONLY  
    4.

    SOURCE OF FUNDS

     

    OO  

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)        ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION  

     

    Delaware  

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH REPORTING PERSON

    WITH

    7.

    SOLE VOTING POWER

           

    8.

    SHARED VOTING POWER

    0

    9.

    SOLE DISPOSITIVE POWER

     

    10.

    SHARED DISPOSITIVE POWER

    0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11)

     

    0%

    14.

    TYPE OF REPORTING PERSON

     

    IA; OO

     

     

     

     

    CUSIP No. 82710M100  SCHEDULE 13D Page 3 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Capital Partners LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)       ¨

    (b)       x

    3. SEC USE ONLY  
    4.

    SOURCE OF FUNDS

     

    OO  

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)        ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION  

     

    Delaware  

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH REPORTING PERSON

    WITH

    7.

    SOLE VOTING POWER

     

    8.

    SHARED VOTING POWER

    0

    9.

    SOLE DISPOSITIVE POWER

     

    10.

    SHARED DISPOSITIVE POWER

    0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11)

     

    0%

    14.

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

     

    CUSIP No. 82710M100  SCHEDULE 13D Page 4 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Supernova Management LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)       ¨

    (b)       x

    3. SEC USE ONLY  
    4.

    SOURCE OF FUNDS

     

    OO  

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)        ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION  

     

    Delaware  

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH REPORTING PERSON

    WITH

    7.

    SOLE VOTING POWER

     

    8.

    SHARED VOTING POWER

    0

    9.

    SOLE DISPOSITIVE POWER

     

    10.

    SHARED DISPOSITIVE POWER

    0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11)

     

    0%

    14.

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

     

    CUSIP No. 589584101  SCHEDULE 13D Page 5 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    David J. Snyderman

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)       ¨

    (b)       x

    3. SEC USE ONLY  
    4.

    SOURCE OF FUNDS

     

    OO  

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)        ¨
    6. 

    CITIZENSHIP OR PLACE OF ORGANIZATION  

     

    United States of America 

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH REPORTING PERSON

    WITH

    7.

    SOLE VOTING POWER

     

    8.

    SHARED VOTING POWER

    0

    9.

    SOLE DISPOSITIVE POWER

     

    10.

    SHARED DISPOSITIVE POWER

    0

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  ¨
    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW(11)

     

    0%

    14.

    TYPE OF REPORTING PERSON

     

    HC; IN

     

     

     

     

    SCHEDULE 13D

     

    This Amendment No. 1 (“Amendment No. 1”) relates to the Statement of Beneficial Ownership on Schedule 13D filed jointly by Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and David J. Snyderman (“Mr. Snyderman”) with the SEC on August 12, 2024, (as amended by this Amendment No. 1, the “Schedule 13D”). This Amendment No. 1 is being filed to report that the Reporting Persons are no longer beneficial owners of more than 5% of the Shares. The filing of this Amendment No. 1 represents the final amendment to this Schedule 13D and constitutes an exit filing for the Reporting Persons.

     

    Except as set forth below, all Items of the Schedule 13D remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

     

    ITEM 4.PURPOSE OF TRANSACTION

     

    Item 4 of the Schedule 13D is hereby amended to add the following information for updating:

     

    Since the filing of the Schedule 13D on August 12, 2024, the Reporting Persons purchased 24,105 Shares between August 13, 2024 and September 16, 2024. All of these Shares were purchased for the benefit of the Managed Account.

     

    Since the filing of the Schedule 13D on August 12, 2024, the Issuer consummated a merger (the “Merger”) pursuant to which each issued and outstanding Share was cancelled and converted into the right to receive $27.50 in cash, without interest. In connection with the Merger, the Reporting Persons’ 2,062,181 Shares, which consisted of 91,063 Shares sold for the benefit of Managed Account, 449,483 Shares sold for the benefit of Systematic Master Fund, 1,431,513 Shares sold for the benefit of PRA Master Fund, and 90,122 Shares sold for the benefit of Relative Value Master Fund, were cancelled and converted into the right to receive $27.50 in cash, without interest.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5(a)-(c) and (e) of the Schedule 13D is hereby amended to add the following information for updating:

     

    (a)           As of the closing of the Merger on September 17, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 0 Shares.

     

    (b)           As of the closing of the Merger on September 17, 2024, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 0 Shares, which represented beneficial ownership of 0% of the Shares.

     

     

     

     

    (c)           The response to Item 4 of this Amendment No. 1 is incorporated herein by reference. Except as set forth in Schedule C and Item 4 of this Amendment No. 1, the Funds had no transactions in the Shares since the filing of the Schedule 13D on August 12, 2024. All of the transactions set forth on Schedule C attached hereto were effected in the ordinary course of business of Magnetar Financial for the Managed Account. The transactions in the Shares set forth on Schedule C were effected in open market transactions on the NASDAQ and various other trading markets.

     

    (d)           As of September 17, 2024, the Reporting Persons ceased to be beneficial owners of more than five percent of the Shares.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 19, 2024

     

      magnetar financial llc
       
      By: Magnetar Capital Partners LP, its Sole Member
      By: Supernova Management LLC, its General Partner
       
      By: /s/ Hayley A. Stein
      Name: Hayley A. Stein
      Title: Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC
       
      magnetar capital partners LP
       
      By: Supernova Management LLC, its General Partner
       
      By: /s/ Hayley A. Stein
      Name: Hayley A. Stein
      Title: Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC
       
      supernova management llc
       
      By: /s/ Hayley A. Stein
      Name: Hayley A. Stein
      Title: Attorney-in-fact for David J. Snyderman, Manager
       
      DAVID J. SNYDERMAN
       
      By: /s/ Hayley A. Stein
      Name: Hayley A. Stein
      Title: Attorney-in-fact for David J. Snyderman

     

     

     

     

    SCHEDULE C

     

    Funds

     

    Date Number of Shares Bought Price Per Share($) (1)(2)
    9/3/2024 5,500 27.12735 (3)
    9/4/2024 18,605 27.11116 (4)

      

    (1) Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average purchase price of $27.12735 per share, at prices ranging from $27.11 to $27.15 per share.

    (4) Reflects a weighted average purchase price of $27.11116 per share, at prices ranging from $27.045 to $27.15 per share.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    99.1   Joint Filing Agreement, dated as of September 19, 2024, among the Reporting Persons.
    99.2   Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on September 19, 2024.

      

     

    Get the next $SILK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SILK

    DatePrice TargetRatingAnalyst
    7/11/2024Buy → Sell
    Argus
    3/7/2024$24.00Hold → Buy
    Argus
    1/19/2024$9.00 → $20.00Hold → Buy
    Stifel
    1/3/2024$20.00Buy
    Lake Street
    10/24/2023Underperform → Peer Perform
    Wolfe Research
    10/11/2023$54.00 → $14.00Buy → Neutral
    B. Riley Securities
    10/11/2023Buy → Neutral
    CL King
    10/11/2023$45.00 → $12.00Buy → Hold
    Stifel
    More analyst ratings

    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zurbay Donald returned 12,610 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:12:36 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Weatherman Elizabeth H returned 155,004 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:08:24 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Lasersohn Jack W returned 16,735 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:01:12 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Silk Road Medical Inc.

      15-12G - Silk Road Medical Inc (0001397702) (Filer)

      9/27/24 4:00:39 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Silk Road Medical Inc.

      EFFECT - Silk Road Medical Inc (0001397702) (Filer)

      9/24/24 12:15:03 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Silk Road Medical Inc.

      25-NSE - Silk Road Medical Inc (0001397702) (Subject)

      9/17/24 9:33:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silk Road Medical downgraded by Argus

      Argus downgraded Silk Road Medical from Buy to Sell

      7/11/24 7:47:06 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Argus with a new price target

      Argus upgraded Silk Road Medical from Hold to Buy and set a new price target of $24.00

      3/7/24 7:36:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Stifel with a new price target

      Stifel upgraded Silk Road Medical from Hold to Buy and set a new price target of $20.00 from $9.00 previously

      1/19/24 8:14:13 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Closes Acquisition of Silk Road Medical, Inc.

      MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (NASDAQ:SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their pa

      9/17/24 8:31:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific

      MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (NASDAQ:SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain a SILK shareholder and question the fairness of the price or have any other concerns, you may contact our firm at the following link to discuss your legal rights at no charge: https:/

      8/19/24 9:31:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Silk Road Medical Names Chas McKhann Chief Executive Officer

      SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal

      11/2/23 8:00:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Announces Retirement of CEO Erica Rogers

      Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand

      10/10/23 4:20:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Names Dr. Tanisha Carino to Board of Directors

      SUNNYVALE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors. Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca.   Prior to Alexion, she serv

      7/26/21 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Announces Results for Second Quarter 2024

      MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.

      7/24/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Reports First Quarter 2024 Financial Results

      SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. "Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact," said Chas McKhann, CEO of Silk Road Medical. "In the first quarter, we made meaningful commercial progress while also taking steps toward sustainable profitability. We enter the second quarter feeling energized by TCAR's outstanding value proposition for physicians and patients and in our opportun

      4/30/24 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care